2. Синопальников А.И. Внебольничная пневмония у взрослых. Consilium Medicum 2009; (2): 128–37.Sinopal’nikov A.I.

3. Чучалин А.Г., Синопальников А.И., Козлов Р.С., Тюрин И. Е., Рачина С.А. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. Смоленск: MAKMAX, 2010.Chuchalin A.G., Sinopal’nikov A.I., Kozlov R.S., Tyurin I. E., Ratchina S.A.

4. Коган М.Б. Острые пневмонии у детей. М.: Медицина, 2013. 144 с.Kogan M.B.

5. Gebo K.A., Moore R.D., Keruly J.C., Chaisson R.E. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect. Dis. 1996; 173: 857–62.

6. Тumbarello M., Tacconelli E., de Gaetano Donati K., Ardito F., Pirronti T., Cauda R. et al. Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998; 18: 39–45.

7. Feikin D.R., Feldman C., Schuchat A., Janoff E.N. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect. Dis. 2004; (4): 445–55.

8. Зимина В.Н., Астафьев А.В. Внебольничные пневмонии у взрослых больных ВИЧ-инфекцией: особенности течения и лечения, профилактика. Пульмонология 2016; 26(4): 488–97.Zimina V.N., Astaf’ev A.V.

9. Selik R.M., Byers R.H., Dworkin M.S. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987–1999. J. Acquir. Immune Defic. Syndr. 2002; 29: 378–87.

10. Kohli R., Yungtai L.О., Howard A.A., Buono D., Floris-Moore M., Klein R.S. et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 2005; 41: 864–72.

11. Chiasson M.A., Berenson L., Li W., Schwartz S., Singh T., Forlenz S. et al. Declining HIV/AIDS mortality in New York City. J. Acquir. Immune Defic. Syndr. 1999; 21: 59–64.

12. Tumbarello M., Tacconelli E., de Gaetano Donati K., Cauda R. HIV-associated bacterial pneumonia in theera of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1999; 20: 208–9.

13. Sullivan J.H., Moore R.D., Keruly J.C., Chaisson R.E. Effect of antiretroviraltherapy on the incidence of bacterial pneumonia in patients with advanced HIV-infection. Am. J. Respir. Crit. Care Med. 2000; 162: 64–7.

14. Puro V., Serraino D., Piselli P., Boumis E., Petrosillo N., Angeletti C. et al. The epidemiology of AIDS associated recurrent bacterial pneumonia in Europe in the pre- and post-HAART periods

15. Floris-Moore M., Lo Y., Klein R.S., Budner N., Gourevitch M., Moskaleva G. et al. Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 2003; 34: 331–7.

16. Puro V., Serraino D., Piselli P., Boumis E., Petrosillo N., Angeletti C. et al. The epidemiology of recurrent bacterial pneumonia in people with AIDS in Europe. Epidemiol. Infect. 2005; 133: 237–43.

17. Kohli R., Lo Y., Homel P., Flanigan T.P., Gardner L.I., Howard A.A., Schoenbaum E.E. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research study. Clin. Infect. Dis. 2006; 43(1): 90–8.

18. Afessa B., Green B. Bacterial pneumonia in hospitalized patients with HIV-infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV study. Ches. 2000; 117(4): 1017–22.

19. Park D.R., Sherbin V.L., Goodman M.S., Pacifico A.D., Rubenfeld G.D., Polissar N.L. et al. The etiology of community acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J. Infect. Dis. 2001; 184(3): 268–77.

20. Rimland D., Navin T.R., Lennox J.L., Jernigan J.A., Kaplan J., Erdman D. et al. Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. AIDS 2002; 16(1): 85–95.

21. van Lieshout M.H.P., de Vos A.F., Dessing M.C., de Porto A., de Boe O.J., de Beer R. et al. ASC and NLRP3 impair host defense during lethal pneumonia caused by serotype 3 Streptococcus pneumoniae in mice. Eur. J. Immunol. 2018; 48: 66–79.

22. Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 2355–65.

23. Xu F., Droemann D., Rupp J., Shen H., Wu X., Goldmann T. et al. Modulation of the inflammatory response to Streptococcus pneumoniae in a model of acute lung tissue infection. Am. J. Respir. Cell Mol. Biol. 2008; 39: 522–9.

24. Janesch P., Stulik L., Rouha H., Varga C., Steinhäuser J., Zerbs M. et al. Age-related changes in the level sand kinetics of pulmonary cytokine and chemokine responses to Streptococcus pneumoniae in mouse pneumonia models. Cytokine 2018; 111: 389–97.

25. David H., Moira K.B., Timothy J.M. Pneumococcal Pneumonia. Mechanisms of Infection and Resolution. Chest 2012; 142(2): 482–91.

26. Баранов А.А., Брико Н.И., Намазова-Баранова Л.С. Современная клинико-эпидемиологическая характеристика пневмококковых инфекций. Лечащий врач 2012; (4). https://www.lvrach.ru/2012/04/ 15435406/Baranov A.A., Briko N.I., Namazova-Baranova L.S.

27. Amaro R., Liapikou A., Cilloniz C., Gabarrus A., Marco F., Sellares J. et al. Predictive and prognostic factors in patients with blood cultura positive community-acquired pneumococcal pneumonia. Eur. Respir. J. 2016; 48(3): 797–807.

28. Николенко В.В., Воробьева Н.Н., Николенко А.В., Окишев М.А. Клинические особенности течения внебольничных пневмоний, вызванных Streptococcus рneumoniaе и Staphylococcus aureus, у ВИЧ-инфицированных пациентов. Пермский медицинский журнал 2016; XXXIII(5): 9–14.Nikolenko V.V., Vorob’eva N.N., Nikolenko A.V., Okishev M.A.

29. Rioseco Z.M.L., Riquelme O.R., Riquelme O.M., Inzunza P.C., Riquelme D.J., Sanhueza R.A. Bacteremic pneumococcal pneumonia in adults admitted to a general hospital. Experience in 60 cases. Rev. Méd. Chile 2018; 146(7): 839–45.

30. Capelastegui A., Zalacain R., Bilbao A., Egurrola M., Ruiz L., Quintana J. et al. Pneumococcal pneumonia: differences according to blood culture results. BMC Pulmonary Medicine. 2014; 14: 128–35.

31. Saindou M., Chidiac C., Miailhes P., Voirin N., Baratin D., Amiri M. et al. Pneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods. HIV Med. 2008; 9: 203–7.

32. Mosquera R., Demier C., Vay C., Famiglietti A., Luna C.M. Impacto de la bacteriemia enunacohorte de pacientes con neumoníaneumocócica. J. Bras. Pneumol. 2012; 38(4): 422–30.

33. Hirschtick R.E., Glassroth J., Jordan M.C., Wilcosky T.C., Wallace J.M., Kvale P.A. Pulmonary Complications of HIV Infection Study Group. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N. Engl. J. Med. 1995; 333(13): 845–51.

34. Biedenbach D.J., Badal R.E., Huang M.Y., Motyl M., Singhal P.K., Kozlov R.S. et al. In vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study. Infect. Dis. Ther. 2016; (5): 139–53.

35. Madeddu G., Porqueddu E.M., Cambosu F., Saba F., Fois A.G., Pirina P. et al. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection 2008; 36(3): 231–6.

36. Benito N., Moreno A., Miro J.M., Torres A. Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur. Res. J. 2012; 39(3): 730–45.

37. Лабораторная диагностика внебольничной пневмонии пневмококковой этиологии: Методические рекомендации. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека; 2017. https://files.stroyinf.ru/Data2/1/ 4293743/4293743035.htm

38. Benito N., Rano A., Moreno A., González J., Luna M., Agustí C. et al. Pulmonary infiltrates in HIV-infected patients in the highly active antiretroviral therapy in Spain. J. Acquir. Immune Defic. Syndr. 2001; 27: 35–43.

39. Benito N., Moreno A., Filella X., Miró J.M., González J., Pumarola T. et al. Inflammatory responses in blood samples of human immunodeficiency virus infected patients with pulmonary infections. Clin. Diagn. Lab. Immunol. 2004; (11): 608–14.

40. Steinhart R., Reingold A.L., Taylor F., Anderson G., Wenger J.D. Invasive Haemophilus influenza infections in men with HIV infection. JAMA 1992; 268: 3350–2.

41. Cordero E., Pachon J., Rivero A., Girón J.A., Gómez-Mateos J., Merino M.D. et al. Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 2000; 30: 461–5.

42. Christensen D., Feldman C., Rossi P., Marrie T., Blasi F., Luna C. et al. HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study. Clin. Infect. Dis. 2005; 41(4): 554–6.

43. Soares R.P.C., de Lira C.R., Cunha M.A.H., Junior V.R.S., de Melo F.L., de Araújo P.S.R. et al. Prevalence of nasal colonization by methicillin-resistant Staphylococcus aureus in outpatients living with HIV/AIDS in a Referential Hospital of the Northeast of Brazil. BMC Res. Notes. 2018; 11(1): 794–801.

44. Tumbarello M., Tacconelli E., de Gaetano Doneti K., Bertagnolio S, Cataldo M., Pirronti T. et al. Nosocomial bacterial pneumonia in human immunodeficiency virus infected subjects: incidence, risk factors and outcome. Eur. Respir. J. 2001; 17: 636–40.

45. Swathirajan C.R., Rameshkumar M.R., Suhas S.S., Vignesh R., Balakrishnan P. Changing drug resistance profile in Pseudomonas aeruginosa infection among HIV patients from 2010–2017 – A retrospective study. J. Glob. Antimicrob. Resist. 2018; 18: